Scarica l'app Stockscreener
1.02
3.81%
-0.03
Precedente Chiudi:
$1.05
Aprire:
$1.03
Volume 24 ore:
11,026
Relative Volume:
0.27
Capitalizzazione di mercato:
$4.03M
Reddito:
-
Utile/perdita netta:
$-9.87M
Rapporto P/E:
-0.0258
EPS:
-39.4678
Flusso di cassa netto:
$-8.76M
1 W Prestazione:
-8.18%
1M Prestazione:
+6.32%
6M Prestazione:
-23.48%
1 anno Prestazione:
-90.85%
Intervallo 1D:
$1.00
$1.03
Intervallo di 1 settimana:
$0.91
$1.10
Portata 52W:
$0.875
$11.60
Revelation Biosciences Inc Stock (REVB) Company Profile
Nome
Revelation Biosciences Inc
Settore
Industria
Telefono
650-800-3717
Indirizzo
4660 LAJOLLA VILLAGE DRIVE, SAN DIEGO
Compare REVB vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REVB
Revelation Biosciences Inc
|
1.0111 | 4.26M | 0 | -9.87M | -8.76M | -39.47 |
VRTX
Vertex Pharmaceuticals Inc
|
542.48 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
797.95 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,025.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
139.72 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
204.12 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Revelation Biosciences Inc Borsa (REVB) Ultime notizie
Price to earnings forward of Revelation Biosciences, Inc. – NASDAQ:REVB - TradingView
Enterprise value to EBIT forward of Revelation Biosciences, Inc. – NASDAQ:REVB - TradingView
Enterprise value to revenue forward of Revelation Biosciences, Inc. – NASDAQ:REVB - TradingView
Revelation Biosciences Grants Performance-Based Restricted Stock to CEO and CFO - Minichart
Form 8K Revelation Biosciences Inc For: 19 August By Investing.com - Investing.com Nigeria
Revelation Biosciences grants restricted stock awards to CEO and CFO - Investing.com
Revelation Biosciences Grants Performance-Based Executive Stock Awards - TipRanks
Revelation Biosciences grants restricted shares to James Rolke and Chester S. Zygmont III - TradingView
Revelation Biosciences (REVB) ties CEO, CFO pay to $30–120M cap tests - Stock Titan
Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study - BioSpace
Revelation Biosciences selects CRO for phase 2/3 AKI study By Investing.com - Investing.com Canada
Revelation Biosciences selects CRO for phase 2/3 AKI study - Investing.com
Revelation Biosciences Selects Avance Clinical As Cro For Phase 2/3 Titan Study - TradingView
Revelation Biosciences (REVB) CFO gifts 416K shares - Stock Titan
Revelation Biosciences (NASDAQ: REVB) grants director 32K restricted shares - Stock Titan
Revelation Biosciences (NASDAQ: REVB) details insider trade - Stock Titan
Revelation Biosciences (REVB) insider logs stock trade in company shares - Stock Titan
Armistice Capital (REVB) discloses 4.99% Revelation Biosciences stake via Master Fund - Stock Titan
REVB Q2 2026 Earnings: Loss per Share Misses Consensus as Pre-Revenue Pipeline AdvancesCFO Commentary Report - Vinanet
Price to book forward of Revelation Biosciences, Inc. – NASDAQ:REVBW - TradingView
Price to sales forward of Revelation Biosciences, Inc. – NASDAQ:REVBW - TradingView
Revelation Biosciences, Inc. (REVBW) Stock Price, News, Quote & History - Yahoo! Finance Canada
Revelation Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Revelation Biosciences reports $3.3M net loss for Q2 2026, $11.5M cash on hand - TradingView
BRIEF-Revelation Biosciences Inc Q2 EPS USD -0.87 - TradingView
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026 - Yahoo Finance
REVELATION BIOSCIENCES 2Q 2026: Net loss $(3.32M), EPS $(0.87) — 10-Q Summary - TradingView
Revelation Biosciences (Nasdaq: REVB) posts Q2 loss and flags cash risk - Stock Titan
REVB Q2'26 Earnings: EPS estimate is (0.83) USD - TradingView
REVB: Q2 net loss widened to $3.3M; Gemini targets a $94B market with cash runway through Q1 2027 - TradingView
Revelation Biosciences Inc expected to post a loss of 83 cents a shareEarnings Preview - TradingView
Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury - New Castle News
Revelation Biosciences (REVB) Holds Steady at $0.99 as Key Support and Resistance Define Trading RangeMESA MA - dars.gov.et
Revelation Biosciences Inc (REVB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Revelation Biosciences Inc (REVB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Revelation Biosciences Inc (REVB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Revelation Biosciences Inc (REVB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
REVB|Revelation Biosciences Inc|Price:1.050|Chg%:-0.010 - TradingKey
Revelation Biosciences Inc (REVB) Valuation: PE, PB & Fair Value Analysis - TradingKey
TradingKey - TradingKey
Revelation Biosciences Inc (REVB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Revelation Biosciences Inc (REVB) Institutional Confidence - TradingKey
Revelation Biosciences Inc (REVB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
REVB|Revelation Biosciences Inc|Price:1.060|Chg%:-0.030 - TradingKey
Revelation Biosciences Inc (REVB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Revelation Biosciences Inc. (REVB) Holds Steady at $1.15 as Consolidation ContinuesSentiment Shift - po-news-eg.net
Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Daily Corinthian
Three New Hires Get Revelation Biosciences Stock Awards Through 2028 - Stock Titan
Revelation Biosciences Adopts Stockholder Rights Plan to Protect Investors and Maximize Value - Minichart
Revelation Biosciences Adopts Stockholder Rights Protection Plan - TipRanks
Why Is Revelation Biosciences (NASDAQ:REVB) in Focus Today? - Kalkine Media
Revelation Biosciences Inc Azioni (REVB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
1.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):